https://www.enterair.pl/slot-gacor/

EPIDEMIOLOGICAL CHARACTERISTICS OF DRUG USE AND EFFECTIVENESS OF METHADONE SUBSTITUTION THERAPY IN HIV-POSITIVE INJECTING DRUG USERS INFECTED WITH VIRAL HEPATITIS C IN MINSK

  • М. А. Shylava Belarusian State Medical University
  • A. V. Abramovich City Clinical Narcological Dispensary
  • I. N. Valchuk Belarusian State Medical University
  • M. L. Dotsenko Belarusian State Medical University
  • G. N. Chistenko Belarusian State Medical University
  • S. V. Zhavoronok Belarusian State Medical University
Keywords: opioids, IDUs, drug users, methadone replacement therapy, opioid replacement therapy, HIV, HCV

Abstract

Background. In 2019 more than 7.6 thousand people were under medical supervision of the drug addiction service of the republic. Many injecting drug users (IDUs) are infected with HIV and viral hepatitis C (HCV) and are the sources of infection for the population. Objective – to analyze the epidemiological characteristics of IDUs of the Republic of Belarus and Minsk, to assess the effectiveness of methadone replacement therapy (MT) in Minsk in 2015-2019 and possible drug interactions in combination therapy for HIV and HCV in association with MT. Material and methods. The data from statistical reporting forms of the City Clinical Narcological Dispensary of Minsk (N=5396) and those of the activities of MT offices in Minsk (N=161) for 2015-2019 were used for the analysis. The obtained data were processed using statistical programs Microsoft Excel 2010, R. Results. It was found out that the proportion of women among IDUs in the republic and Minsk didn’t exceed20%. Among IDUs are predominantly 26-30-year-olds (23.07% in the republic, 33.27% in Minsk), individuals with secondary education (47% and 55.11% respectively), unmarried individuals (54% and 53.39% respectively). The share of HIV-positive program participants coinfected with viral hepatitis C (HCV) is 100.00% and among the IDUs admitted to the program, the proportion of participants with HIV-positive status is growing significantly (rate of increase is 26.32% 100.00, p<0.05) in 2019. Conclusions. The absence of the effect of direct-acting antivirals for the treatment of HCV on the pharmacokinetics and pharmacodynamics of methadone may contribute to replacement therapy adherence.

References


1.United Nations. World drug report 2019 [Internet]. Available from: https://wdr.unodc.org/wdr2019/prelaunch/WDR2019_B1_R.pdf.

Harm Reduction International. The Global State of Harm Reduction 2018 [Internet]. Available from: https://www.hri.global/files/2019/02/05/global-state-harm-reduction-2018.pdf.

Vinnickaja AG, Razvodovskij JuE, Lelevich VV. Ocenka chislennosti inekcionnyh potrebitelej narkotikov v Belarusi s ispolzovaniem metoda povtornogo zahvata [Estimating the number of injecting drug users in Belarus using the recapture method]. Voprosy narkologii. 2011;(5):46-50. (Russian).

Statkevich I, Samarina O, Truhan L, Pechko T, Pospelova V, KonojkoT, Ryzhkovskaja Ju, Goncharova S, Moskaleva I, Martynchik D. Snizhenie vreda: argumenty v polzu strategicheskih investicij. Nacionalnyj otchet Respubliki Belarus. Minsk; 2015. 61 p. (Russian).

Fisenko EG. Rasprostranenie VICh i parenteralnyh gepatitov sredi kljuchevyh grupp naselenija s vysokim riskom inficirovanija VICh. In: Parenteralnye virusnye infekcii: sovremennye vozmozhnosti diagnostiki i lechenija. Materialy Respublikanskogo nauchno-prakticheskogo seminara s mezhdunarodnym uchastiem; 2019 Sent. 26; Minsk. Minsk; 2019. (Russian).

Ugolovnyj kodeks Respubliki Belarus (Jul. 9, 1999, No. 275-Z). S izmenenijami i dopolnenijami (Jul. 17, 2018, No. 131-Z). Tekst po sostojaniju na 18 Jun. 2019. Minsk: Akademija MVD; 2019. 239 p. (Russian).

Grankov VI. VICh i parenteralnye virusnye gepatity v Evropejskom regione VOZ: vyzovy i perspektivy [HIV and parenteral viral hepatitis in the WHO European Region: challenges and prospects]. In: Parenteralnye virusnye infekcii: sovremennye vozmozhnosti diagnostiki i lechenija. Materialy Respublikanskogo nauchno-prakticheskogo seminara s mezhdunarodnym uchastiem; 2019 Sent. 26; Minsk. Minsk; 2019. (Russian).

EACS. Guidelines – European AIDS Clinical Society. Version 10.0. November 2019 [Internet]. Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.

Epclusa. Prescribing Information, Gilead Science Inc. November 2019 [Internet]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf.

Harvoni. Summary of Product Characteristics, Gilead Sciences Ltd. August 2019 [Internet]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.

Harvoni. Prescribing Information, Gilead Sciences Inc. August 2019 [Internet]. Available from: https://www.medicines.org.uk/emc/product/3461/smpc.

Denning JM. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics. Hepatology. 2011;54(4):372.

Sovaldi. Summary of Product Characteristics, Gilead Sciences Inc. January 2014 [Internet]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2014/1/european-commission-grants-marketing-authorization-for-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c-infection.

Sovaldi. Prescribing Information, Gilead Sciences Ltd. December 2013 [Internet]. Available from: https://www.medicines.org.uk/emc/product/5247/smpc.

Published
2020-06-03
How to Cite
1.
ShylavaМА, Abramovich AV, Valchuk IN, Dotsenko ML, Chistenko GN, Zhavoronok SV. EPIDEMIOLOGICAL CHARACTERISTICS OF DRUG USE AND EFFECTIVENESS OF METHADONE SUBSTITUTION THERAPY IN HIV-POSITIVE INJECTING DRUG USERS INFECTED WITH VIRAL HEPATITIS C IN MINSK. journalHandG [Internet]. 2020Jun.3 [cited 2024May16];4(1):81-5. Available from: http://www.journal-grsmu.by/index.php/journalHandG/article/view/142
Section
Оригинальные исследования
slot gacor hari ini